113 related articles for article (PubMed ID: 21053460)
1. [Rational application of tumor marker CA 125 in gynecological oncology].
Durdević S; Stojanović S; Marijana BN; Maksimović M
Med Pregl; 2010; 63(3-4):195-9. PubMed ID: 21053460
[TBL] [Abstract][Full Text] [Related]
2. Serum alpha L-fucosidase enzyme activity in ovarian and other female genital tract tumors.
Abdel-Aleem H; Ahmed A; Sabra AM; Zakhari M; Soliman M; Hamed H
Int J Gynaecol Obstet; 1996 Dec; 55(3):273-9. PubMed ID: 9003953
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
4. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
5. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
[TBL] [Abstract][Full Text] [Related]
6. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
Shabana A; Onsrud M
Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
Inaba N; Negishi Y; Fukasawa I; Okajima Y; Ota Y; Tanaka K; Matsui H; Iwasaki H; Sudo H; Tanaka N
Tumour Biol; 1995; 16(6):345-52. PubMed ID: 7569681
[TBL] [Abstract][Full Text] [Related]
8. CA 125 in gynecological pathology--a review.
Kenemans P; Yedema CA; Bon GG; von Mensdorff-Pouilly S
Eur J Obstet Gynecol Reprod Biol; 1993 Apr; 49(1-2):115-24. PubMed ID: 8365505
[TBL] [Abstract][Full Text] [Related]
9. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.
Bon GG; Kenemans P; Verstraeten R; van Kamp GJ; Hilgers J
Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):107-14. PubMed ID: 8571992
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
Zou L; He X; Zhang JW
Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
[TBL] [Abstract][Full Text] [Related]
11. Cirrhotic ascites, ovarian carcinoma, and CA-125.
Rubin J; Rockey DC
South Med J; 1999 Feb; 92(2):248-50. PubMed ID: 10071679
[TBL] [Abstract][Full Text] [Related]
12. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
Onsrud M; Shabana A; Austgulen R
Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
[TBL] [Abstract][Full Text] [Related]
13. CA 15-3 as a tumor marker in gynecological malignancies.
Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Mancuso S
Gynecol Oncol; 1988 Jun; 30(2):265-73. PubMed ID: 3163666
[TBL] [Abstract][Full Text] [Related]
14. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
15. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.
Escudero JM; Auge JM; Filella X; Torne A; Pahisa J; Molina R
Clin Chem; 2011 Nov; 57(11):1534-44. PubMed ID: 21933899
[TBL] [Abstract][Full Text] [Related]
16. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
18. CA 72-4 serum marker--a new tool in the management of carcinoma patients.
Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Cavaliere F; Casaldi V; Wappner G; Abbolito MR; Greiner JW
Cancer Invest; 1995; 13(2):227-38. PubMed ID: 7874576
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
Fan HY; Duan DM; Liu YF
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]